BioCardia (NASDAQ:BCDA) Posts Earnings Results

BioCardia (NASDAQ:BCDA) issued its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, FiscalAI reports.

Here are the key takeaways from BioCardia’s conference call:

• CardiAMP showed consistent clinical signals — phase III echo data trended toward significance in the full cohort (LV volume p≈0.06–0.09) and delivered statistically significant, clinically meaningful reductions in LV volumes in the pre‑specified high NT‑proBNP subgroup (p=0.02 and 0.01), consistent with reduced MACE and improved quality of life across three trials.
• Management is pursuing near‑term regulatory pathways — an imminent Q‑Submission to FDA CBER (breakthrough designation), a Helix De Novo submission under CDRH review, and a forthcoming PMDA consultation in Japan are positioned as upcoming approval catalysts.
• Confirmatory trial progress — the CardiAMP HF II study is underway at four active sites and may be used either as a randomized confirmatory trial or converted into a post‑marketing registry depending on FDA/PMDA feedback, with enrollment deliberately paced while regulatory discussions proceed.
• Financial runway is constrained — year‑end cash was $2.5M, 2025 operating cash use was ~ $7.5M, and net loss widened modestly, indicating limited near‑term liquidity unless financing, partnerships, or regulatory milestones occur.
• Competitive and business‑development context — other cell therapies (mostly surgically delivered) are advancing in Japan and the U.S.; BioCardia highlights its minimally invasive, cost‑effective approach and says partnerships interest may grow if the HF approval path advances.

BioCardia Trading Up 0.4%

NASDAQ BCDA opened at $1.21 on Wednesday. The stock has a 50-day simple moving average of $1.24 and a 200 day simple moving average of $1.35. The company has a market capitalization of $12.79 million, a PE ratio of -0.81 and a beta of 0.60. BioCardia has a 12 month low of $1.00 and a 12 month high of $3.20.

Key BioCardia News

Here are the key news stories impacting BioCardia this week:

• Positive Sentiment: Management says an FDA submission for the CardiAMP therapy is imminent and highlights trial data that the company interprets as signaling clinical benefit — a clear regulatory catalyst if submission timing and data interpretation hold. BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit
• Positive Sentiment: Q4 2025 earnings call and accompanying coverage emphasize promising clinical results and plan milestones that could unlock value if regulatory interactions progress as described. Investors typically reward clear development timelines and positive clinical messaging. BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid …
• Positive Sentiment: Full earnings-call transcript provides management commentary on data, regulatory timing and next steps — useful for investors parsing whether upcoming catalysts are achievable. BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Company filed its 2025 Form 10‑K and issued a business highlights release summarizing 2025 results and strategy — transparency and a formal filing reduce execution risk and help institutional investors confirm progress. BioCardia Reports 2025 Business Highlights and Financial Results
• Neutral Sentiment: Quarterly results showed an EPS loss (reported ($0.06) for the quarter); this is expected for a clinical-stage company and doesn’t materially change the valuation framework unless guidance or cash runway were updated. MarketBeat BCDA summary (EPS and trading data)
• Neutral Sentiment: Multiple short‑interest reports appear to show zero reported short positions and contain anomalous “NaN” changes — data seems unreliable, so there’s no clear sign of meaningful short pressure altering price action. (Repeated data entries.)
• Negative Sentiment: Risks remain: the company is still loss-making, has a small market cap and analyst estimates show negative EPS for the year — downside remains if clinical/regulatory milestones slip or if funding needs increase.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $25.00.

Hedge Funds Weigh In On BioCardia

Several institutional investors have recently modified their holdings of BCDA. Cetera Investment Advisers bought a new position in BioCardia during the second quarter worth about $40,000. Geode Capital Management LLC raised its position in shares of BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares during the period. Finally, DRW Securities LLC bought a new position in shares of BioCardia during the 4th quarter valued at about $72,000. 20.57% of the stock is currently owned by institutional investors and hedge funds.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.